Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients
This study aims to establish a tolerable dose level and regimen of RAD001 in combination with cisplatin and etoposide (standard-of-care chemotherapy) in patients with extensive stage small-cell lung cancer (SCLC) who have not previously been treated with systemic chemotherapy.
Checked against the public recordLast updated Dec 21, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Novartis Pharmaceuticals
- Interventions being studied
- Drug: Everolimus
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion criteria: * Patients with histologically or cytologically confirmed diagnosis of extensive disease small-cell lung cancer (ED SCLC) * Age ≥ 18 years * WHO Performance Status Grade ≤ 1 (ie. ability to perform normal daily functions) * Adequate bone marrow, liver and renal function Exclusion criteria: * Chronic steroid treatment * Prior treatment with chemotherapy for advanced lung cancer * Prior treatment with mTOR inhibitors * Active bleeding conditions, skin conditions, gastrointestinal disorders, mouth ulcers, eye conditions, chronic liver or kidney disorders, uncontrolled diabetes, infections or other severe medical conditions * Symptomatic or uncontrolled brain metastases * Other cancers within the past 5 years * Pregnant or breastfeeding women Other protocol-defined inclusion/exclusion criteria may apply.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Highlands Oncology GroupFayetteville, Arkansas
- University of Colorado Health Sciences CenterAurora, Colorado
- Dana Faber Cancer InstituteBoston, Massachusetts
- MD Anderson Cancer CenterHouston, Texas
- Cancer Therapy and Research Center at UTHSCSASan Antonio, Texas
- Novartis Investigative SiteParis
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 21, 2020. Always confirm current availability with the study team.